Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib Re-challenge in EGFR Mutation Positive NSCLC (ICARUS)
NCT01530334Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2012
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoints: Objective Response Rate and Clinical Benefit Rate. Started Jul 2012; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01530334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01530334.